The following information is obtained from various newswires,
published medical journal articles, and medical conference presentations.
Company: Forest Laboratories
Approval Status: Approved February 1998
Treatment for: chronic stable angina
General Information
Tiazac has been approved for use in the treatment of chronic stable angina. Tiazac was previously approved for the treatment of hypertension.
Clinical Results
Tiazac has been shown to significantly reduce both angina attack rates and nitroglycerin consumption. Tiazac's central effects and peripheral vasodilating action balanced oxygen supply and demand producing significantly greater increases in total duration of exercise compared to placebo. Additionally, Tiazac effectively reduced blood pressure of hypertensive patients over a 24-hour dosing interval.
Side Effects
Side Effects: The side-effect profile is comparable to placebo, even when dosed up to 360 mg.
Mechanism of Action
Tiazac (diltiazem HCl) is a once-daily calcium channel blocker.
